The Guardian: Anthropic set the share price for its debut on the US stock market at $83 on Wednesday, positioning the artificial intelligence company for one of the biggest initial public offerings in history. The firm is slated to begin trading on Thursday under the ticker symbol ANT. When Anthropic filed for its IPO last month, the company detailed rapidly rising revenue in its prospectus. Despite the increasing revenue, Anthropic disclosed a net loss of $80bn for the first half of 2026.

Comment: Despite attempts by the envious media to deliver a crash in the AI space, ANT has been able to get its IPO away, albeit perhaps rather below the high-water mark value which could have been $2tn. A net loss of $80bn for the first half of this year would normally be significant, but given the schmoozing the company’s investment bankers have done, who cares? Everyone has the chance of getting in at the IPO, and being 20-30% down in short order. Sounds compelling.

Cobra (COBR),  a South Australian mineral exploration and development company advancing the Wudinna Rare Earth Project and the Manna Hill Copper Project, is pleased to announce that its Australian subsidiaries have been successful in securing non-dilutive funding under the Government of South Australia’s Plan for Accelerating Exploration (“PACE”) Minerals programme. The proposed co-funding comprises up to A$300,000 for the Wudinna Rare Earth Project and up to A$200,000 for the Manna Hill Copper–Gold Project.

Comment: Usually, when one sees that a company in almost any area has been handed a non-dilutive cheque from the government, it tends to be a small amount which in this case in relative terms it is. But along with the recent fundraise, and with the signal of support in high places, the mood music here is certainly positive.

88 Energy Limited (88E)  announced that it has entered into a binding memorandum of understanding with Forte Energy Limited (ASX: FEL) (Forte) to consolidate and advance an expanded acreage position at the Kad River East Project on Alaska's North Slope through a joint venture (the JV). The transaction will combine 88E's seven existing Kad River East lease blocks with one additional State lease block for which 88E's subsidiary, Captivate Energy Alaska, Inc. (Captivate), was the apparent highest bidder in the State of Alaska's 2026 North Slope Areawide lease sale, establishing a consolidated project area of approximately 20,354 gross acres (~12,212 net acres to 88 Energy). Formal award of the new lease block by the State of Alaska is expected between May and July 2027. Under the arrangement, 88 Energy will retain operatorship and a 60% working interest, with Forte holding the remaining 40%. The expanded acreage is fully covered by the existing Kad River 3D seismic dataset, providing a strong technical foundation for prospect generation and resource evaluation ahead of a proposed farm-out campaign targeted for H2 CY2027.

Comment: One covers 88E occasionally, in the hope that one day the company will in whatever way get over the line. That said, even though today’s update sounds constructive, we have the shares at year lows. Those looking for a serious inflection point may have to wait until well into the new year.

The Smarter Web Company (SWC)  announces that, on 18 November 2026, it purchased 3,265 of its MORE Preferred Shares at a price of £77.50 per Preferred Share. The aggregate total consideration was £253,925 and was funded from the Coinbase Strategic Credit Facility and cash resources. The purchase was made pursuant to the authority granted at the Company’s General Meeting on 28 September 2026. The Company's purchase at £77.50 per Preferred Share represents a discount of approximately 13.89% to MORE's original £90 offer price per Preferred Share under the prospectus published by the Company on 29 September 2026. The purchased Preferred Shares will be held in treasury and will not carry any entitlement to dividends while so held. Following the purchase, 206,072 Preferred Shares remain in issue, excluding the total 5,040 Preferred Shares held in treasury. Of these, 99,975 are held by or on behalf of Tennyson Capital under the Company’s Preferred Shares at-the-market facility.

Comment: While it has been crunch point for SWC since the Bitcoin Treasury bubble burst in summer 2025, one could argue that still keeping the dream alive over a year later is something of a miracle. However, with BTC half its highs and sinking like a stone, buying Preferred Shares or buying scratch cards seems to be academic at this time.

Hemogenyx Pharmaceuticals plc (HEMO),  the clinical-stage biopharmaceutical group, announced that its Chairman, Professor Sir Marc Feldmann, has been awarded the Robert Koch Medal in Gold by the Robert Koch Foundation in recognition of his lifetime achievement in immunology. The medal, conferred by the Foundation for a scientist's life's work, was presented at its award ceremony at the Robert Koch Institute in Berlin on 13 November 2026.

Comment: While I wait for my Lifetime Achievement Award for services to the stock market (David Stredder of Mello Events got one), one has to congratulate the good Professor on his gong as he is a very decent chap. That said, it is a shame that much of his good work came before he became Chairman of HEMO, as the company could do with a bit of an acceleration in progress. 

Alkemy Capital Investments plc (ALK),  the 100% owner of Tees Valley Lithium ("TVL"), announces that TVL has signed an amendment to its existing binding offtake agreement with a wholly-owned subsidiary of Glencore plc for battery-grade lithium hydroxide from TVL's refinery in Teesside, UK. Under the amended agreement, Glencore is committed to take all battery-grade lithium hydroxide that TVL makes available to it, up to 25,000 tonnes per annum. ALK said “Securing a binding offtake agreement with Glencore covering up to 100% of Train 1’s planned production capacity is a major commercial milestone for the UK’s flagship lithium refiner, Tees Valley Lithium. Glencore’s commitment to purchase up to 25,000 tonnes annually over an initial eight-year term provides a contracted route to market for our entire planned first train output, while preserving flexibility to supply strategic customers directly. Together with the UK Government’s DRIVE35 offer in principle and our established technology partnership with Veolia, this agreement marks further progress in addressing the commercial and delivery requirements of the project. Our focus remains on building strategically important lithium refining capacity in Teesside.”

Comment: One understands that this is just an offtake agreement and not money in the bank, but ordinarily even sharing a tube carriage with someone from Glencore would and should be enough to cause a share price to rocket. The fact that this has not happened for ALK is a tribute to the London stock market and the reason so many companies either do not list here or want to leave. Yes, “tribute” is sarcasm.

KR1 plc (KR1) , a London Stock Exchange-listed onchain infrastructure company, announced the launch of DIEM infrastructure operations, building on its Venice update of 12 November 2026. DIEM is Venice’s inference token, providing daily credits for running artificial intelligence (“AI”) models. KR1 monetises this capacity by supplying access to customers through third-party marketplaces. The Company currently holds 557 DIEM, acquired separately from its holding of VVV, Venice’s native token. Each staked DIEM provides US$1 of daily credit to run AI models on Venice. In the 90 days to 16 November 2026, KR1 used the inference capacity from its DIEM holdings to fulfil approximately 1.92 million third-party customer requests through Surplus Intelligence, serving 101.5 billion AI model tokens. KR1 said, “The convergence of AI and crypto is opening new markets for KR1’s capital and operational expertise. DIEM shows our model in practice: digital assets generating income from AI demand while we retain the underlying holdings.”

Comment: The good news for anyone with an IQ under 160 who does not understand KR1 RNS announcements, is that you are not alone. It is the case with many tech / biotech companies that they think blinding us with science like the Thomas Dolby song is the way to go. That said, even one would presume the late Dr Magnus Pike would appreciate the assurance that a marriage between AI and crypto can be a good thing.

B HODL Plc (AQSE: HODL),  the first British company founded to Buy, Hold, Deploy and Compound Bitcoin, announces that Freddie New has given notice in writing of his intention to resign as Chief Executive Officer and as a director of the Company. Freddie remains Chief Executive Officer and a director, and will support the Board in ensuring an orderly handover. Upon his departure, the Company intends to appoint and announce a new CEO. Freddie is leaving to return to a legal and advisory role in the Bitcoin industry, having maintained his legal practising certificate throughout his term as CEO. He will remain a significant minority shareholder in the Company and intends to support the Board and the Company as such in the future. The Company will release a further announcement to the market on his final day in office.

Comment: Although this is not quite up to the level of Robbie Williams leaving Take That, it is disappointing that our Freddie has decided to head off for pastures new – pun intended. One wonders if HODL will be inundated with his potential successors? One hears that Jensen Huang is at a loose end these days. Nevertheless, this news does hint that all is not well even at the best-funded BTC Treasury companies, especially after the latest dip for cryptos.

Delta Gold Technologies (AQSE:DGQ)  - Holding(s) in Company. Purebond goes up from 3.63% to 5.61%.

Comment: The big deal at DGQ that set off the big rally and presumably destroyed enough bears and market makers to mean that the company keeps getting defamed (yes, that is how it works), was that Purebond was on the shareholder register. Interestingly enough they have only just gone above 5%, so actually the recent setback for the shares may have run its course if the mudslinging does not start again.

Avacta Therapeutics (AVCT),  a life sciences company developing innovative, targeted oncology drugs, today announces the presentation of new preclinical data showing that AVA6207, a Next-Generation pre|CISION® dual payload peptide-drug conjugate (PDC), reversed topoisomerase 1 inhibitor (TOP1i) resistance in vitro and in animal models with TOP1i-resistant tumors. The Company is presenting these studies today at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Comment: One hears that Barcelona is wonderful this time of year, 19 C is very pleasant. As far as AVCT is concerned, the one inch at a time progress announced periodically in a journey that could go on ad infinitum may give the shares a temporary boost. That said, this has already gone on and cost more than all but the stalwarts appreciate. At least one hopes that the 50p area is the main support here.

Quantum Data Energy PLC (QDE)  announces, further to its previous RNS announcement dated 5 October 2026, that its Bordesley 5 MW flexible generation power project, which is fully funded in partnership with Power Balancing Services Ltd (“PBS”) as previously announced, has completed construction and commissioning within timeline and budget, has successfully entered commercial operations and is now generating and trading electricity in the UK wholesale market. Bordesley is the Company’s third operational flexible generation asset, alongside its Pyebridge 8.1 MW flexgen asset and its Hindlip 7.5 MW flexgen asset.

Comment: Shares of QDE have been trying to find a base near to 2p in the recent past, with the recent steady as we go RNS announcements seeming to help in this respect. The main thing in the near term is to be meaningfully commercial as soon as possible, something which we dare to say seems to be happening.

Scancell Holdings plc (SCLP),  a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumour immune responses in difficult-to-treat cancers, today provided an update on progress across its clinical and preclinical pipeline, including the grant of Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for inzitagene plasmivec and new data from the Phase 2 ModiFY trial of Modi-1. Dr Phillip L’Huillier, Chief Executive Officer, Scancell, commented: “We are very encouraged by the progress across our pipeline. The new data from the ongoing ModiFY trial, demonstrate that Modi-1 can induce vaccine-specific immune responses in a subset of patients with renal cell carcinoma (RCC), with these responses being associated with longer progression-free survival. These findings provide encouraging evidence of clinical activity of our Moditope platform and support further evaluation of Modi-1. Our next steps will focus on better understanding these immune responses, exploring potential biomarkers and using these insights to inform future clinical development.”

Comment: One might have thought that the mere mention of the FDA would be enough to light a fire under the share price of SCLP, and give us a re-run of the massive April – May rally. However, today’s holding pattern RNS is probably not the one to relight the fire of the bulls, especially while the shares are capped by the 50 day moving average at 90p.